Orthofix Medical (NasdaqGS:OFIX) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Orthofix Medical to reach your target.
Hmm, we can't give any reliable projection for Orthofix Medical's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.
None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!
| Advantages | Disadvantages | Neutral |
|---|---|---|
|
|
|
| OFIX Price (Orthofix Medical stock price per share) |
$6.07 | |
| PE Ratio versus Sector | 1620% higher than other Unknown stocks | |
| PE Ratio versus Industry | 865% higher than other Unknown stocks | |
| Cash Yield | 14.63% | |
| Free Cash Flow Jitter | 209% |
In the six months to 2026-11-22, no insider bought shares, and 2 insiders sold in 5 trades, about $52 thousand.
The six months before that had 4 buys and 19 sales.
Open-market buys and sells reported by Orthofix Medical's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-11-02 | Fisher Patrick (President, Global Limb Recon) | Sell | 150 | $9.07 |
| 2026-10-01 | Fisher Patrick (President, Global Limb Recon) | Sell | 150 | $9.44 |
| 2026-09-01 | Fisher Patrick (President, Global Limb Recon) | Sell | 150 | $9.39 |
| 2026-08-18 | Fisher Patrick (President, Global Limb Recon) | Sell | 1,295 | $10.09 |
| 2026-06-18 | McPherron Aviva (Pres, Global Ops & Qual) | Sell | 3,670 | $9.38 |
| 2026-05-07 | HENNEMAN JOHN B III | Buy | 5,000 | $12.26 |
| 2026-04-16 | Cedron Jorge Andres (CLO) | Sell | 3,743 | $12.82 |
| 2026-03-17 | Vitale Lucas (CP&BOO) | Sell | 4,269 | $11.92 |
| 2026-03-10 | CAPPS VICKIE L | Buy | 100 | $12.44 |
| 2026-03-10 | CAPPS VICKIE L | Buy | 2,400 | $12.45 |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 2,173,386 shares shorted. With 40,435,353 shares available for purchase and an average trading volume over the past 10 trading days of 819,690, it would take at least 2.7 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
How to read this: what free cash flow is, why earnings matter.
Over the 6 fiscal years from 2010 to 2025 with positive net income, operating cash flow totaled $275 million against net income of $113 million, or 2.44 times. Net income was negative in 10 of the 16 years, and those years are left out of the ratio.
In 2025, net income was -$92.2 million and operating cash flow was $33.3 million, so no ratio is shown for that year.
In 2025, capital expenditures were $34.6 million, 103.8% of operating cash flow of $33.3 million, which leaves an estimated -$1.3 million after capex. Across the 14 years with reported capex, it averaged 51.6% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2010 | 44.3 | 42.3 | 25.8 | 0.96 |
| 2011 | -17.7 | 64.7 | 25 | n/a |
| 2012 | 42.9 | 10.2 | 28 | 0.24 |
| 2013 | -28.8 | 67 | 24.8 | n/a |
| 2014 | -8.5 | 51.2 | 18.1 | n/a |
| 2015 | -2.8 | 43.6 | 27.2 | n/a |
| 2016 | 3.1 | 59.1 | 16.4 | 19.33 |
| 2017 | 6.2 | 39 | 14.7 | 6.26 |
| 2018 | 13.8 | 49.9 | 13.6 | 3.61 |
| 2019 | -28.5 | 32 | 19 | n/a |
| 2020 | 2.5 | 74.3 | 15.5 | 29.51 |
| 2021 | -38.4 | 18.5 | 17.8 | n/a |
| 2022 | -19.7 | -11.5 | 23.2 | n/a |
| 2023 | -151 | -45.8 | 62 | n/a |
| 2024 | -126 | 25.8 | 34.9 | n/a |
| 2025 | -92.2 | 33.3 | 34.6 | n/a |
How to read this: why companies buy back shares, dividend yield explained.
Over the 4 fiscal years from 2009 to 2016 with dividend or share repurchase facts, estimated free cash flow totaled $127 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.
In 3 of the 4 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $114 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.
In 2016, cash spent repurchasing shares was $63.4 million, 175.3% of estimated free cash flow of $36.2 million. That was more than the estimated free cash flow of the year.
| Fiscal year | Estimated free cash flow (USD millions) | Dividends paid (USD millions) | Cash spent repurchasing shares (USD millions) | Total returned (USD millions) | Total as a percent of estimated free cash flow |
|---|---|---|---|---|---|
| 2009 | 29.7 | n/a | 0.2 | 0.2 | 0.7% |
| 2013 | 42.1 | n/a | 39.5 | 39.5 | 93.7% |
| 2015 | 19 | n/a | 11.6 | 11.6 | 60.9% |
| 2016 | 36.2 | n/a | 63.4 | 63.4 | 175.3% |
Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.
How to read this: earnings and margins.
Revenue was $546 million in 2009 and $822 million in 2025, a compound annual growth rate of 2.6% over 16 years.
Revenue rose 2.9% from 2024 to 2025.
Our estimated free cash flow was -$1.2 million in 2025, a negative margin of 0.1% of revenue, meaning the estimate was below zero. In 2009 the estimated margin was 5.4%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2009 | 546 | 29.7 | 5.4% |
| 2010 | 463 | 18.9 | 4.1% |
| 2011 | 436 | 40.8 | 9.4% |
| 2012 | 440 | -14.8 | -3.4% |
| 2013 | 398 | 42.1 | 10.6% |
| 2014 | 402 | 26.8 | 6.7% |
| 2015 | 396 | 19 | 4.8% |
| 2016 | 410 | 36.2 | 8.8% |
| 2017 | 434 | 18.7 | 4.3% |
| 2018 | 453 | 31.9 | 7.0% |
| 2019 | 460 | 13.9 | 3.0% |
| 2020 | 407 | 58.4 | 14.4% |
| 2021 | 464 | 2.4 | 0.5% |
| 2022 | 461 | -29.3 | -6.4% |
| 2023 | 747 | -73.2 | -9.8% |
| 2024 | 799 | -4.9 | -0.6% |
| 2025 | 822 | -1.2 | -0.1% |
How to read this: how debt and assets are compared, the current ratio.
In 2025, cash and equivalents were $82 million against total liabilities of $401 million, or 20.5% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 47.1% of total assets in 2025, compared with 50.2% in 2010, a decrease of 3.1 percentage points.
Stockholders equity was $450 million in 2025, compared with $301 million in 2010, a rise of 49.6%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was -0.2% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2010 | 604 | 13.6 | 303 | 301 |
| 2011 | 619 | 32.7 | 339 | 280 |
| 2012 | 681 | 30.8 | 324 | 356 |
| 2013 | 464 | 28.9 | 168 | 296 |
| 2014 | 393 | 36.8 | 93.3 | 300 |
| 2015 | 400 | 63.7 | 110 | 290 |
| 2016 | 372 | 39.6 | 109 | 263 |
| 2017 | 405 | 81.2 | 109 | 297 |
| 2018 | 467 | 69.6 | 131 | 335 |
| 2019 | 496 | 69.7 | 168 | 328 |
| 2020 | 526 | 96.3 | 169 | 357 |
| 2021 | 477 | 87.8 | 140 | 337 |
| 2022 | 459 | 50.7 | 122 | 337 |
| 2023 | 925 | 33.1 | 327 | 599 |
| 2024 | 893 | 83.2 | 390 | 503 |
| 2025 | 851 | 82 | 401 | 450 |
Free cash flow was positive in 12 out of 17 reported years for Orthofix Medical, using only its current SEC filer.
Year-to-year variability in free cash flow is volatile, measured at 209%.
We do not estimate a fair value for Orthofix Medical while its free cash flow growth is not positive, so there is no value comparison here.
Dividends are not in our data for Orthofix Medical.
Our value investing guide explains how to test these numbers against the filings themselves.
Every fiscal year on this page is reported by one SEC filer, CIK 884624.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: OFIX annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Orthofix Medical have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to OFIX: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is the Difference Between Trading Stocks and Investing?
Why Do Companies Perform Stock Buybacks?
How Does Portfolio Churning Affect Your Returns?
How Do Tariffs Affect the Stock Market?
DCA vs Lump Sum: 155 Years of S&P 500 Historical Data
How to Invest $1000 in the Stock Market